Tokushima, Japan

Takafuni Fujioka

This inventor holds 1 USPTO granted patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takafuni Fujioka. Retrieved from https://idiyas.com/inventor/takafuni-fujioka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 86(Granted Patents)


Company Filing History:


Years Active: 1988

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Takafuni Fujioka: Innovator in Antihistamic Agents

Introduction

Takafuni Fujioka is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of carbostyril derivatives. His work focuses on creating compounds that exhibit antihistamic and central nervous controlling actions.

Latest Patents

Takafuni Fujioka holds a patent for "Pharmaceutically useful carbostyril derivatives." This patent describes carbostyril derivatives that are effective as antihistamic agents or central nervous controlling agents. The derivatives are represented by a complex general formula, which includes various substituents that enhance their pharmacological properties. He has 1 patent to his name.

Career Highlights

Fujioka is associated with Otsuka Pharmaceutical Company, Limited, where he continues to innovate in the pharmaceutical sector. His research has contributed to advancements in medications that target allergic reactions and central nervous system disorders.

Collaborations

Throughout his career, Takafuni Fujioka has collaborated with esteemed colleagues such as Kazuo Banno and Kazuyuki Nakagawa. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical agents.

Conclusion

Takafuni Fujioka's work in developing carbostyril derivatives showcases his commitment to advancing pharmaceutical science. His contributions are vital in the ongoing quest for effective antihistamic treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…